MARKET

RGNX

RGNX

Regenxbio
NASDAQ
8.63
+0.25
+2.98%
After Hours: 8.63 0 0.00% 17:49 04/01 EDT
OPEN
8.61
PREV CLOSE
8.38
HIGH
8.90
LOW
8.42
VOLUME
526.75K
TURNOVER
--
52 WEEK HIGH
16.19
52 WEEK LOW
5.04
MARKET CAP
445.42M
P/E (TTM)
-2.2956
1D
5D
1M
3M
1Y
5Y
1D
STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY, LLP
PR Newswire · 18h ago
Weekly Report: what happened at RGNX last week (0323-0327)?
Weekly Report · 2d ago
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit
PR Newswire · 2d ago
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR Newswire · 2d ago
Regenxbio shares drop 17.8% due to RGX-111 securities class action; lead plaintiff deadline set for April 14, 2026
Reuters · 6d ago
SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD
PR Newswire · 6d ago
FDA Clears Denali Therapeutics Drug As First Brain-Penetrating Biologic For Rare Disease
Benzinga · 6d ago
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit
PR Newswire · 03/24 22:36
More
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.

Webull offers Regenxbio Inc stock information, including NASDAQ: RGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RGNX stock methods without spending real money on the virtual paper trading platform.